Replies to post #413450 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

bas2020...

Let's review, again, the results of the "P3" AD trial...

1. All endpoints met: ADAS-Cog, ADCS-ADL and CDR-SB.

2. Odds Ratios highlighting the Super Responders for both Cog and ADL.

KEM and subgroup analysis, MRI results and Study data are forthcoming to detail the efficacy aspects and demonstrate additional benefits in the study.

It's that simple.

YUP, or , we can just drag this on until someone finally buries us w/piles of strong RWE-RWD and happy RSD kids signing in a choir....